We serve Chemical Name:Levobupivacaine CAS:27262-47-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Levobupivacaine
CAS.NO:27262-47-1
Synonyms:2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-, (2S)-;(2S)-1-Butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide;L-(-)-Bupivacaine;2′,6′-Pipecoloxylidide,1-butyl-,L-(-);1-Butyl-N-(2,6-dimethylphenyl)-piperidine-2-carboxamide;(-)-Bupivacaine;Levobupivacaine;1-butyl-piperidine-2-carboxylic acid-(2,6-dimethyl-anilide);(S)-(-)-Bupivacaine;(S)-Bupivacaine;(2S)-1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide
Molecular Formula:C18H28N2O
Molecular Weight:288.428
HS Code:2933399090
Physical and Chemical Properties:
Melting point:254ºC (dec.)(lit.)
Boiling point:423.4±45.0 °C at 760 mmHg
Density:1.0±0.1 g/cm3
Index of Refraction:1.547
PSA:32.34000
Exact Mass:288.220154
LogP:3.64
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 2811 6
Packing Group:
Contact us for information like 2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-, (2S)- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(2S)-1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(2S)-1-Butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Use and application,(2S)-1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide technical grade,usp/ep/jp grade.
Related News: Johnson & Johnson’s COVID-19 vaccine presents greater benefits than it does safety risks, especially amid the quickly spreading Delta variant, a key CDC expert panel decided. However, the panel said that a ruling over the need for a booster added to all COVID shots will have to start with the FDA. Methyl 2-[(5S,8S)-5-(3,4-dichlorophenyl)-8-(methylamino)-5,6,7,8-tetrahydro-2-naphthalenyl]acetate manufacturers In addition, AstraZeneca is exploring the potential of anifrolumab in a variety of diseases where type I interferon plays a key role, including lupus nephritis, cutaneous lupus erythematosus and myositis. 3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-1-(isopropylamino)quinolin-2(1H)-one sodium salt suppliers These sites operate under cGMP conditions and have been inspected and approved by leading global pharmaceutical companies and regulatory authorities, including the US FDA. (6aR,11bR)-9-Methoxy-6,6a,11b-trimethyl-6a,11b-dihydro-benzo[c]fluoren-7-one vendor & factory.
